Scroll To Top

FDA Approves Neuropathy Treatment

FDA Approves Neuropathy Treatment


The Food and Drug Administration recently approved Gamunex, an immune globulin intravenous therapy, for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a condition characterized by progressive weakness and impaired sensory function in the arms and legs. Immune globulin products are obtained from pooled human blood plasma, which contains infection-fighting antibodies, and are often given to HIVers at risk for certain infectious diseases. It is estimated that CIDP affects about 25,000 Americans.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors